The anti-cancer activities of jasmonates Ziv RavivSharon CohenDortit Reischer-Pelech Review Article 30 November 2012 Pages: 275 - 285
Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer Siddharth ChachadShrinivas PurandareRaghu Naidu Original Article 23 October 2012 Pages: 287 - 292
Effect of topical chamomile on immunohistochemical levels of IL-1β and TNF-α in 5-fluorouracil-induced oral mucositis in hamsters Marina CurraMarco Antonio T. MartinsManoela D. Martins Original Article 25 October 2012 Pages: 293 - 299
CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients Andreas TrojanAthanasios VergopoulosWolfgang Joechle Original Article 26 October 2012 Pages: 301 - 306
Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma D. Ross CamidgeNormand BlaisLaura Q. Chow Original Article 30 October 2012 Pages: 307 - 319
A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer M. MichaelJ. ZalcbergN. C. Tebbutt Original Article 30 October 2012 Pages: 321 - 330
In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts Jianxia GuoDana M. ClausenJulie L. Eiseman Original Article 30 October 2012 Pages: 331 - 344
Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer Fumihiro OshitaMakiko SugiuraKouzo Yamada Original Article 03 November 2012 Pages: 345 - 350
Pharmacokinetic study and effectiveness evaluation of slow-release PLGA-5-fluorouracil microsphere Jingquan LiYongdong PuMudan Zhu Original Article 08 November 2012 Pages: 351 - 359
Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study F. MuellerB. BüchelM. Joerger Original Article 09 November 2012 Pages: 361 - 370
Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma Cui ChenFeng-hua WangYu-hong Li Original Article 10 November 2012 Pages: 371 - 378
In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation Wei-Hua HaoJong-Jing WangKuang-Yang Hsu Original Article 10 November 2012 Pages: 379 - 388
Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver Apostolia M. TsimberidouMark B. LeickRazelle Kurzrock Original Article 11 November 2012 Pages: 389 - 397
Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma Cormac OwensValerie LaurenceOdile Oberlin Original Article 17 November 2012 Pages: 399 - 404
Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer Sachi MoritaKeisuke UeharaYuichi Ando Original Article 17 November 2012 Pages: 405 - 411
Combination of three cytotoxic agents in small-cell lung cancer G. P. StathopoulosD. TrafalisD. Tsavdaridis Original Article Open access 18 November 2012 Pages: 413 - 418
Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection Yoshiaki MurakamiKenichiro UemuraTaijiro Sueda Original Article 21 November 2012 Pages: 419 - 429
Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis Wei-Xiang QiFeng LinZan Shen Original Article 21 November 2012 Pages: 431 - 439
Autophagy, cell death and sustained senescence arrest in B16/F10 melanoma cells and HCT-116 colon carcinoma cells in response to the novel microtubule poison, JG-03-14 Jonathan W. BiggersTuyen NguyenDavid A. Gewirtz Original Article 21 November 2012 Pages: 441 - 455
Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion Kazuhiro KitamuraKaoru KubotaAkihiko Gemma Original Article 21 November 2012 Pages: 457 - 461
A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors Raoul TibesGil FineAnthony W. Tolcher Original Article 23 November 2012 Pages: 463 - 471
Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters Tim A. D. SmithM. Virginia C. L. AppleyardAlastair M. Thompson Original Article 24 November 2012 Pages: 473 - 480
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy Sun Jin SymJunshik HongDong Bok Shin Original Article 29 November 2012 Pages: 481 - 488
Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration Matthew HoffmannClaudia KasserraGondi Kumar Original Article Open access 01 December 2012 Pages: 489 - 501
Amelioration of cisplatin-induced nephrotoxicity in peroxiredoxin I-deficient mice Kosuke OkadaDongmei MaToru Yanagawa Original Article 11 December 2012 Pages: 503 - 509
Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305) Soichiro ShibuiYoshitaka NaritaKazuhiro Nomura Original Article 11 December 2012 Pages: 511 - 521
A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors Luis E. RaezKyriakos PapadopoulosTheodore J. Lampidis Clinical Trial Report 11 December 2012 Pages: 523 - 530
Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed? Peggy GandiaCécile ArellanoEtienne Chatelut Short Communication 27 November 2012 Pages: 531 - 536
Modulation of multidrug resistance gene expression in peripheral blood mononuclear cells of lung cancer patients and evaluation of their clinical significance Consolación MelguizoJose PradosAntonia Aránega Short Communication 24 November 2012 Pages: 537 - 541
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours U. LassenW. H. MillerM. B. Sawyer Short Communication 30 November 2012 Pages: 543 - 549
Erratum to: Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation Yoon-Koo KangByung Woog KangMin-Hee Ryu Erratum 13 January 2013 Pages: 551 - 552
Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 Bojana Milojkovic KerklaanVeronique DiérasAhmad Awada Erratum 18 January 2013 Pages: 553 - 553